Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL3 | P15374 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 15/20 | 0.47 |
| ▸ | MAP3K7 | O43318 | 3/20 | 0.43 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22895403 | 0.78 | UCHL3 (0.52) | UCHL3EGFRMAP3K7MAP2K1MAPK1 | |
| SCHEMBL22895377 | 0.75 | CCNK (0.67) | — | |
| SCHEMBL27361372 | 0.73 | UCHL3 (0.51) | UCHL3EGFRMAPKAPK2 | |
| SCHEMBL30935288 | 0.72 | UCHL3 (0.48) | UCHL3EGFRMAPKAPK2 | |
| SCHEMBL21816616 | 0.72 | EGFR (0.59) | UCHL3EGFR | |
| SCHEMBL16095355 | 0.72 | EGFR (0.51) | UCHL3EGFRMAPKAPK2 | |
| SCHEMBL16095969 | 0.72 | EGFR (0.58) | UCHL3EGFRMAPKAPK2 | |
| SCHEMBL24726489 | 0.71 | EGFR (0.54) | UCHL3EGFR | |
| SCHEMBL23606806 | 0.71 | UCHL3 (0.46) | UCHL3EGFRMAP3K7MAP2K1SRC | |
| SCHEMBL31348830 | 0.71 | EGFR (0.53) | UCHL3EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10894788-B2 | Inhibitors of cyclin-dependent kinases | KINNATE BIOPHARMA INC. (US) | 2021-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10894788-B2 | Inhibitors of cyclin-dependent kinases | CDK2, CCNK, CDK1 | UCHL3 3083/4885EGFR 1247/4885MAP3K7 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.